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stem/progenitor cells into two patients with
advanced liver cirrhosis
Vincenzo Cardinale1†, Guido Carpino2†, Raffaele Gentile1, Chiara Napoletano3, Hassan Rahimi3,
Antonio Franchitto4,5, Rossella Semeraro1, Marianna Nuti3, Paolo Onori4, Pasquale Bartolomeo Berloco6,
Massimo Rossi6, Daniela Bosco3, Roberto Brunelli7, Alice Fraveto1, Cristina Napoli1, Alessia Torrice1, Manuela Gatto1,
Rosanna Venere1, Carlo Bastianelli7, Camilla Aliberti7, Filippo Maria Salvatori8, Luciano Bresadola8, Mario Bezzi8,
Adolfo Francesco Attili9, Lola Reid10, Eugenio Gaudio4† and Domenico Alvaro1,5*†Abstract
Background: Efforts to identify cell sources and approaches for cell therapy of liver diseases are ongoing, taking
into consideration the limits recognized for adult liver tissue and for other forms of stem cells. In the present study,
we described the first procedure of via hepatic artery transplantation of human fetal biliary tree stem cells in
patients with advanced cirrhosis.
Methods: The cells were immune-sorted from human fetal biliary tree by protocols in accordance with current
good manufacturing practice (cGMP) and extensively characterized. Two patients with advanced liver cirrhosis
(Child-Pugh C) have been submitted to the procedure and observed through a 12 months follow-up.
Results: The resulting procedure was found absolutely safe. Immuno-suppressants were not required, and the patients did
not display any adverse effects correlated with cell transplantation or suggestive of immunological complications. From a
clinical point of view, both patients showed biochemical and clinical improvement during the 6 month follow-up
and the second patient maintained a stable improvement for 12 months.
Conclusion: This report represents proof of the concept that the human fetal biliary tree stem cells are a
suitable and large source for cell therapy of liver cirrhosis. The isolation procedure can be carried out under
cGMP conditions and, finally, the infusion procedure is easy and safe for the patients. This represents the basis
for forthcoming controlled clinical trials.
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Human biliary tree stem/progenitor cells (hBTSCs) have
been isolated from fetal and adult large intrahepatic and
extrahepatic bile ducts and found to reside within the
peribiliary glands (PBGs) and crypts of gallbladder epi-
thelium [1,2]. The hBTSCs were able to self-replicate in
culture and to differentiate into mature hepatocytes, cho-
langiocyte, or pancreatic β-cells in vitro and in vivo [3-5].* Correspondence: domenico.alvaro@uniroma1.it
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unless otherwise stated.The aim of this study was to evaluate the safety and the
feasibility of a therapeutic protocol for advanced liver cir-
rhosis based on transplantation of hBTSCs.
Methods
Human fetal livers
The study was approved by the local ethics committee
of Sapienza University Hospital. The livers from human
fetuses consisted of one of gestational age of 18 weeks
and used in patient#1 (male), and one of gestational age
of 20 weeks and used in patient#2 (female). They were
obtained by elective pregnancy termination from the De-
partment of Gynecology (Sapienza, University of Rome,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have independently signed the consent to the abortion,
and after the abortion has been initiated by the adminis-
tration of the drug for the delivery induction.
Serologic negativity for infectious diseases (HCV, HBV,
HIV, EBV, HEV, HDV, toxoplasmosis, rubella, cytomegalo-
virus, parvovirus, herpes simplex type 1 and 2, TPHA)
was documented in the mother as required by current
regulation. Both fetuses presented severe cardiac malfor-
mations but no chromosomal alterations as demonstrated
by karyotype analysis. To avoid prolonged ischemia we
performed a monitoring of the fetal cardiac beat every
3 hours during the abortion procedure. The fetal livers
(fetus#1: 8 g weight; fetus#2: 12 g weight) including biliary
tree and gallbladder were procured immediately after de-
livery and transported in refrigerated organ transport
cases. A small fragment was taken for histology.
Isolation of hBTSCs
The extrahepatic biliary tree (including the gallbladder)
was maintained in position by pins at the hilum; the
more peripheral liver parenchyma was detached from
the biliary tree with a scraper. Successively, the entire
biliary tree and the remaining parenchyma were further
disaggregated gently by scalpel and a MACS dissociator
(Miltenyi Biotec), and digested in buffer containing 300
U/ml type I Collagenase (Sigma Aldrich) and 0.3 mg/ml
deoxyribonuclease (Sigma Aldrich) for 20–30 min at
37°C. Freshly isolated cells were immunoselected for
EpCAM-positive cells using magnetic beads (Miltenyi
biotec) [5,6]. The sorting resulted in isolation of 42 million
viable cells from the first fetus and 60 million from the
second one. The duration of the isolation procedure
averaged 5 hours. Cells were suspended in sterile 10%
glucose solution at 1 million cells per ml and main-
tained for 45 minutes under controlled temperature of
4°C before infusion. All the procedures were carried
out according to “The rules governing medicinal products
in the European Union” and the European guidelines of
GMP for medicinal products for human use (EudraLex-
Volume 4 Good manufacturing practice Guidelines). Cell
products were evaluated by standard sterility tests for
gram+, gram-, aerobic and anaerobic bacteria, mycetes
and with endotoxins tests, and characterized immedi-
ately by Flow Cytometry (FC) for EpCAM (Miltenyi
Biotec, CD326/EpCAM-FITC, human; dilution 1:50) and
LGR5 (OriGene, LGR5-PE, human; dilution 1:50) before
transplantation in the patients.
Patients’ inclusion and exclusion criteria
The inclusion criteria were: 1. Child-Pugh class C (score =
or >10), and 2. Patients who were not candidates for liver
transplantation because of their age being greater than
65 years and because of surgical or anesthetic risk.3. Informed consents were obtained from the patients
undergoing to the cell infusion procedure. The exclu-
sion criteria were: 1. Patients with contraindications to
hepatic artery cannulation; 2. Chronic hepatic encephal-
opathy that renders unenforceable the request of informed
consent; 3. Patients with portal vein thrombosis; 4. Active
alcoholism; 5. Active infections; 6. Primary liver cancers
or liver metastases; 6. Spontaneous Bacterial Peritonitis; 7.
Hepato-renal syndrome. Written informed consent was
obtained from the patients for publication of their clinical
details and any accompanying images. A copies of the
written consents are available for review by the Editor of
this journal. The study was approved by our local Ethic
Committee, Policlinico Umberto I/Sapienza University of
Rome and was non-sponsored (protocol code, 1951).
Other methological details were furnished in Additional
file 1.Results
In situ characterization of EpCAM-positive cells in fetal
biliary tree and liver
In fetal tissues, EpCAM was expressed by cells at different
anatomical portions of the intrahepatic and extrahepatic
biliary tree (Figure 1). Interestingly, most EpCAM-positive
cells co-expressed LGR5. In fetal livers, LGR5-positive
cells were located in the ductal plate and in the epithelium
of larger bile ducts. In gallbladder and hepatic common
duct, surface epithelial cells and bud of PBGs were dif-
fusely positive for LGR5.Control tests and characterization of cell product
Estimated cell viability by trypan blue exclusion was rou-
tinely higher than 95%. All the microbiology tests resulted
negative. The FC analyses of the first sample before
EpCAM sorting, indicated that 30.5% of the freshly iso-
lated cells were EpCAM-positive (Figure 1). The immuno-
magnetic sorting enriched for cells with co-expression of
EpCAM and LGR5 (46.5%). A restricted sub-population
was composed of EpCAM-negative but LGR5-positive
cells (10.0%). The FC analyses of the second sample
showed that, before sorting, 20.5% of the freshly isolated
cells were EpCAM-positive. The immunomagnetic sorting
enriched the EpCAM-positive population to 51% and con-
tained cells with co-expression of EpCAM and LGR5
(48.4%). A significant sub-population was composed of
EpCAM-negative but LGR5-positive cells (20.5%).
Immunosorted EpCAM-positive cells were suspended
in 10% glucose solution, at a concentration of 1 million
cells per ml. The cell suspension was infused into the
hepatic artery at an infusion velocity of 200 ml/h. The
first patient presented an anatomical variant of the ori-
gin of the common hepatic artery. He received, via the
right hepatic artery, 42 millions viable EpCAM-sorted
Figure 1 Immunphenotype of biliary tree stem/progenitor cells and flow cytometry of transplated cells. A) Expression of EpCAM and
LGR5 in human fetal livers and extrahepatic biliary tree. Double immunofluorescence for EpCAM (green) and LGR5 (red) in human fetal liver.
Larger intrahepatic bile ducts are EpCAM and LGR5 positive. scale bar = 50 μm. Epithelial cells of gallbladder are EpCAM and LGR5 positive
(arrows). scale bar = 50 μm. Cells in surface epithelium are EpCAM and LGR5 positive (arrows). Cells in peribilary glands are mostly EpCAM-
negative and LGR5-positive (arrowheads). scale bar = 50 μm. B) Flow cytometry plot for EpCAM and LGR5 of cell suspension prepared for patient
#1. FC analysis of cell suspensions prepared for patient #1 and #2.
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60 millions viable EpCAM-sorted cells.
Clinical outcome
The clinical and biochemical parameters of the two cir-
rhotic patients transplanted with hBTSCs are given inTable 1 Clinical and biochemical parameters during the follow
Patient #1 Male, 73 ys/old Baseline 2nd month
Child-Pugh score 12 10
MELD score 24 21
Bilirubin (mg/dl) 12.06 10.37
Albumin (g/dl) 3.0 3.3
INR 2.07 1.69
Creatinine (mg/dl) 0.6 0.6
Patient #2 Female, 71 ys/old Baseline 2nd month
Child-Pugh score 11 10
MELD score 21 17
Bilirubin (mg/dl) 3.04 2.38
Albumin (g/dl) 3.2 3.24
INR 2.00 1.82
Creatinine (mg/dl) 1.30 1.10Table 1. The first patient was a 73-year Caucasian male
affected by HCV-related liver cirrhosis. The patient was
also affected by auto-immune hemolytic anemia diag-
nosed 3–4 years before treatment. Table 1 shows the
time course of significant biochemical and clinical pa-
rameters during the follow-up. Interestingly, albumin-up
3rd month 6th month 12th month
11 10 12
21 20 25
9.06 10.19 14.96
3.04 3.18 3.2
1.77 1.57 2.1
0.7 0.7 0.8
3rd month 6th month 12th month
9 8 8
19 16 16
2.80 2.80 2.88
3.69 3.80 4.00
1.90 1.60 1.60
1.20 1.08 1.07
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a gradual and constant decrease of INR. Before treat-
ment, the patient received repeated hospitalizations,
mostly for treatment of ascites trough large volume
paracentesis but, their duration was significantly short-
ened by the cell therapy (1-day vs 5-days hospital stay
pre-treatment). The need of paracentesis was signifi-
cantly reduced during the follow-up, with no request
after cell therapy. Compressively, the control of ascites
and the disappearance of leg edema were associated
with a weight loss of 6 kg. The patient observed the
same pharmacological treatment during the whole period
of observation, and did not received albumin injection.
Total bilirubin showed a separate kinetic pattern with re-
spect to the other hepatic tests being affected by auto-
immune hemolytic anemia. Six months after receiving
hBTSC transplantation (Table 1) the Child-Pugh score de-
creased from C-12 to C-10 and, MELD score from 24 to
20, mainly due to improvement of coagulation and ascites.
In the second semester of observation the patients dis-
played a gradual but constant worsening of liver functions
(Table 1) with Child-Pugh’s and MELD scores returning
to pretreatment values. However, in the same period, the
patient underwent a femoral neck fracture complicated by
pneumonia and died on October 2013 for pulmonary
edema. With respect to the second patient, she is a
Caucasian female patient affected by HCV-related cirrho-
sis. No side-effects related to the cell infusion were regis-
tered during the scheduled 6-month follow-up. Six
months after the treatment (Table 1), the patient displayed
a consistent amelioration of liver function: Child-Pugh
score from C-11 to B-8, MELD score from 21 to 16. As
illustrated in Table 1, after 12th month of follow-up the
patient continued to maintain a state of compensated liver
cirrhosis. Notably, patient #2 experienced a gradual and
constant amelioration of albumin value and coagulation
(INR) along the 12 months follow-up as showed in the
Table 1. The patient did not receive intravenous albumin
infusion.
Discussion
Our proposal overcomes limitations of hepatocyte-based
therapy [7,8] given the large availability of fetal tissues
from therapeutic abortions and of adult biliary tree tis-
sue typically discarded in liver and pancreatic transplant-
ation procedures. Moreover, our cell isolation procedure
represents a further advance since Khan et al. [9] did not
include extrahepatic biliary tree or gallbladder that are
tissues enriched in EpCAM/LGR5 positive cells. As far
as cell product characterization, FACS analysis allowed
us to evaluate the phenotype of the companion cells
after cell sorting. They consisted of cells of mesenchymal
origin (white blood, hematopoietic, stromal and endo-
thelial cells) [4-6,10,11]. This apparent contamination isdue to the fact that in the cases of solid organs the di-
gestion procedure does not allow complete destruction
of the cell-cell interactions [6]. The purity of the cell
product could be further increased by culture strategy
[4,5,10]. As far as clinical outcomes, during the whole
period of the strict follow-up we did not observed any
increase in necrosis indexes nor signs of rejection such
as LDH, transaminases, inflammatory indexes (reactive
C protein, sedimetry, leucocyte count). Here, the absence
of signs of rejection and/or allergy without any immune-
suppressive regimen, correlates with minimal or null ex-
pression of HLA class I and II antigens both in hepatic
and biliary tree stem cells from fetal liver [5,6,9,10]. We
have recently confirmed these data in our setting, showing
how EpCAM-positive hBTSCs, residing in ductal plates
and along the entire biliary tree, strongly express FAS lig-
and [10]. In this study, in in vitro experiments on hBTSCs
co-cultured with T lymphocytes, FAS-mediated apoptosis
of CD4 and CD8 T cells was induced [10]. EpCAM-
sorted cells from fetal livers have been used already in
clinical trials of cell therapy of advanced liver cirrhosis
without the need of immune-suppressants [6,9]. Here,
from a clinical point of view, both patients showed
biochemical and clinical improvement during the
6 month follow-up and the second patient maintained
a stable improvement for 12 months. Thus the 6th month
should result the more appropriate for a re-treatment.
The lack of cell tracking in our report reduces its scientific
value. However, using the same infusion route, Khan et al.
[9] demonstrated, by a scintigraphic method, the effective
engraftment in the liver.
Conclusions
Our report represents the basis for protocols of future
clinical trials. First of all, we employed minimal invasive-
ness in the procedure. These aspects have been demon-
strated in this report as the patients were 71 and 74 years
old and with advanced liver cirrhosis. The entire cell pro-
duction was carried out in a certified cell factory accom-
plishing all the “European guidelines of GMP for medicinal
products for human use”. Finally, an identity test was per-
formed before the cell injection. Moreover, we performed a
monitoring of the fetal cardiac beat every 3 hours during
the abortion procedure, and processed tissues experienced
less than 3 hours of in uterus cardiac beat absence.
Additional file
Additional file 1: Supplementary Material.
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